- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Bill Pushes Legislation to Restore Medicare Funding for Cancer Treatments
A new bill, Cancer Patient Protection Act of 2013 (HR 1416), is aiming to restore Medicare reimbursements for anti-cancer drugs and biologicals to pre-sequester levels
A new bill, Cancer Patient Protection Act of 2013 (HR 1416), is aiming to restore Medicare reimbursements for anti-cancer drugs and biologicals to pre-sequester levels. Because cancer treatment regimens are costly, they have been highly affected by the sequester cuts. ACCC Buzz reports:
After a recent hearing by the House Energy and Commerce Health Subcommittee, the Cancer Patient Protection Act of 2013 (HR 1416) is gaining support. The bi-partisan bill was introduced by Congresswoman Renee Ellmers and now enjoys 97 co-sponsors.
Our fight is not over, however. ACCC continues to educate other members of the House about the importance of this legislation. ACCC recently met with Representative Erik Paulsen’s office, who is one of the latest members to sign onto HR 1416. We are continuing to work to identify a champion in the Senate.
Read the full story here: http://bit.ly/15mNCLo
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
